Cargando…

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capalbo, Carlo, Scafetta, Giorgia, Filetti, Marco, Marchetti, Paolo, Bartolazzi, Armando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479404/ https://www.ncbi.nlm.nih.gov/pubmed/30935099 http://dx.doi.org/10.3390/ijms20071607

Ejemplares similares

Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo
por: Peplau, Emanuel, et al.
Publicado: (2021)

Galectins in Cancer and Translational Medicine: From Bench to Bedside
por: Bartolazzi, Armando
Publicado: (2018)

Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using ((89)Zr)-DFO- Galectin3-F(ab')(2) mAb
por: Varasteh, Zohreh, et al.
Publicado: (2021)

Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives
por: Bartolazzi, Armando, et al.
Publicado: (2018)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

Oncogenic miR-9 is a target of erlotinib in NSCLCs
por: Chen, Xi, et al.
Publicado: (2015)

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs
por: Lypova, Nadiia, et al.
Publicado: (2021)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
por: De Felice, Francesca, et al.
Publicado: (2015)

Personalized post-surgical care?—possible strategies for NSCLCs with EGFR mutation
por: Suda, Kenichi
Publicado: (2020)

Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC
por: Rossi, Alessandro, et al.
Publicado: (2021)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

CT based radiomic approach on first line pembrolizumab in lung cancer
por: Zerunian, Marta, et al.
Publicado: (2021)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock, Alexa B, et al.
Publicado: (2020)

Galectin-3 Impairment of MYCN-Dependent Apoptosis-Sensitive Phenotype Is Antagonized by Nutlin-3 in Neuroblastoma Cells
por: Veschi, Veronica, et al.
Publicado: (2012)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid Carcinomas
por: Lavra, Luca, et al.
Publicado: (2011)

Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors
por: Cui, Bopei, et al.
Publicado: (2023)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors
por: Manzo, Ciro, et al.
Publicado: (2021)

Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors
por: Veschi, V, et al.
Publicado: (2014)

Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach
por: Baldelli, Elisa, et al.
Publicado: (2022)

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
por: Liberini, Virginia, et al.
Publicado: (2021)

Thyroid Cancer Imaging In Vivo by Targeting the Anti-Apoptotic Molecule Galectin-3
por: Bartolazzi, Armando, et al.
Publicado: (2008)

BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
por: Wang, Mingxing, et al.
Publicado: (2017)

Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
por: Hong, Se Hyang, et al.
Publicado: (2020)

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study
por: Gu, Linping, et al.
Publicado: (2022)

Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology
por: Carpi, A, et al.
Publicado: (2006)

Role of Galectins in Tumors and in Clinical Immunotherapy
por: Chou, Feng-Cheng, et al.
Publicado: (2018)

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
por: Mazzotta, Marco, et al.
Publicado: (2020)

Anti-angiogenic efficacy of 5′-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs
por: Yuan, Dongmei, et al.
Publicado: (2015)

Oxidative DNA double strand breaks and autophagy in the antitumor effect of sterically hindered platinum(II) complexes in NSCLCs
por: Chen, Feihong, et al.
Publicado: (2017)

Metastatic NSCLCs With Limited Tissues: How to Effectively Identify Driver Alterations to Guide Targeted Therapy in Chinese Patients
por: Li, Weihua, et al.
Publicado: (2021)

The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs
por: Bortolotto, Chandra, et al.
Publicado: (2023)

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors
por: Rajani, Karishma R., et al.
Publicado: (2015)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Galectins as Cancer Biomarkers
por: Balan, Vitaly, et al.
Publicado: (2010)

Delineating the "galectin signature" of the tumor microenvironment
por: Compagno, Daniel, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_iefelsitak156hrtnb85jn1fp3